Reasons to Retain Cardinal Health Stock in Your Portfolio for Now

Cardinal Health expects fiscal 2027 Pharma segment profit growth of 8-11% and Other-business profit growth of 15-18%, while consensus forecasts revenue of $266.02 billion (+4.6%) and adjusted EPS of $12.55 (+11.5%). Fiscal 2026 earnings beat estimates in each of the past four quarters, and fiscal 2027 EPS estimates have risen 4.2% over 60 days. IRA-related pricing changes are expected to moderate Pharma revenue growth to 3-5%, while specialty growth is projected to slow from about 25% toward the historical mid-teens range; sustained input-cost inflation or a prolonged Iran conflict could push GMPD profit toward the lower end of its $200-$220 million guidance. Shares are up 13.4% year to date, and the article recommends retaining the stock for now.

Analysis

The key debate is earnings quality, not headline revenue. IRA-driven price reductions can depress reported Pharma sales without an equivalent profit hit if distribution economics are preserved; the risk is that weaker nominal growth obscures volume or mix deterioration and compresses the multiple before earnings estimates move. Conversely, generic conversions and contract wins matter only if they translate into segment profit and cash generation—not simply throughput.

The faster-growing businesses could gradually improve CAH’s earnings mix, but their smaller base means 15–18% profit growth there may not offset a stumble in the much larger Pharma operation. Specialty deceleration from an unusually strong year is a likely expectations risk over the next 1–3 months, even if growth remains healthy. GMPD is the more direct near-term earnings downside: persistent fuel/resin inflation or tariff offsets failing would pressure the segment toward the low end of guidance. Longer term, execution in nuclear/precision health and logistics could make CAH less dependent on low-growth distribution economics.

After significant year-to-date outperformance, the bullish outlook appears partly reflected; the article provides no valuation or peer-estimate data to support chasing. Compare CAH’s segment-profit progression and guidance revisions with Cencora and McKesson before expressing a distributor pair. The thesis weakens if Pharma profit growth falls below guidance, GMPD misses its range, or Other-business profit growth fails to convert into consolidated earnings. It strengthens if estimates rise on profit—not revenue alone—and service/customer retention remain intact.

Key Decisions for Investors

• Maintain existing CAH exposure, but avoid adding solely on the reported revenue outlook or recent momentum; seek confirmation in Pharma and Other-business segment profit and cash conversion.
• Over the next 1–3 months, track Specialty growth against the mid-teens trajectory, GMPD performance versus its $200–$220 million profit range, and any guidance or consensus EPS revisions. A downgrade in either segment would be a reason to reduce risk.
• Set a relative-value watch against Cencora and McKesson rather than initiating a pair now: first compare valuation, segment-profit growth, and IRA-related exposure. The supplied information is insufficient to establish a defensible relative-value entry.
• Treat elevated fuel/resin costs and tariff offsets as a near-term alert; sustained input inflation or escalation in the cited geopolitical risk would make GMPD the clearest downside channel.